Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human-to-human Transmission
100%
Hantavirus Pulmonary Syndrome
100%
Hospital Setting
100%
Chilean
100%
Healthcare Workers
50%
Southern Chile
33%
Febrile Respiratory Illness
33%
Virus
16%
Epidemiological Study
16%
Antibody Prevalence
16%
Hospitalization
16%
Enzyme-linked Immunosorbent Assay (ELISA)
16%
Potential Risk Factors
16%
ARGENTINA
16%
Hospital Type
16%
Hantavirus
16%
No Significant Difference
16%
Immunoglobulin G
16%
Immunoglobulin IgM
16%
Immunoglobulin G Antibodies
16%
GloVe
16%
Standardized Questionnaire
16%
Andes Hantavirus
16%
Andes Virus
16%
Hospital Activity
16%
Recent Outbreaks
16%
Positive-negative
16%
Hospitalization Rate
16%
Antibody-negative
16%
Regional Hospital
16%
Serological Studies
16%
Respiratory Protection
16%
Nursing and Health Professions
Hospital Setting
100%
Hantavirus Pulmonary Syndrome
100%
Health Care Personnel
50%
Respiratory Tract Disease
33%
Enzyme Linked Immunosorbent Assay
16%
Immunoglobulin G Antibody
16%
Antibody Titer
16%
Immunoglobulin M
16%
Immunoglobulin G
16%
Medicine and Dentistry
Hantavirus Pulmonary Syndrome
100%
Health Care Personnel
50%
Respiratory Disease
33%
Hantavirus
33%
Prevalence
16%
Secretion (Process)
16%
Enzyme Linked Immunosorbent Assay
16%
Immunoglobulin G
16%
Immunoglobulin M
16%
Immunoglobulin G Antibody
16%
Andes Virus
16%
Virus
16%
Pharmacology, Toxicology and Pharmaceutical Science
Hantavirus Pulmonary Syndrome
100%
Respiratory Tract Disease
33%
Hantavirus
33%
Enzyme-Linked Immunosorbent Assay
16%
Prevalence
16%
Immunoglobulin G Antibody
16%
Immunoglobulin M
16%
Immunoglobulin G
16%
Andes Virus
16%
Virus
16%